Skip Navigation


Annals of Oncology Advance Access originally published online on November 10, 2005
Annals of Oncology 2006 17(1):141-145; doi:10.1093/annonc/mdj037
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
17/1/141    most recent
mdj037v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by de Jong, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by de Jong, D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology

Lymphocyte-rich classical Hodgkin lymphoma (LRCHL): clinico-pathological characteristics and outcome of a rare entity

D. de Jong1,*, J. Bosq2, K. A. MacLennan3, J. Diebold4, J. Audouin4, J. Chasle5, A.-M. Mandard5, J. Marnay5, M. Henry-Amar5 On behalf of the European Organization for Research and Treatment of Cancer (EORTC) Lymphoma Group and the Groupe d'Étude des Lymphomes de l'Adulte (GELA)

1 The Netherlands Cancer Institute, Amsterdam, the Netherlands; 2 Institut Gustave Roussy, Villejuif, France; 3 St. James's University Hospital, Leeds, UK; 4 Hôtel-Dieu, Paris, France; 5 Centre François Baclesse, Caen, France

* Correspondence to: Dr D. de Jong, The Netherlands Cancer Institute, Department of Pathology, Plesmanlaan 1211066 CX Amsterdam, The Netherlands. Tel: +31-20-512-752; Fax: +31-20-512-2759; E-mail: d.d.jong{at}nki.nl

Background: To investigate the proportion, clinical characteristics and outcome of lymphocyte-rich classical Hodgkin lymphoma (LRCHL) in relation to nodular lymphocyte predominant HL (NLPHL) and classical HL (cHL).

Patients and methods: A series of 2743 HL patients of all stages enrolled into three EORTC trials (H7, H8, H34) conducted between 1988 and 2000 and forming an unbiased series of HL patients was studied.

Results: Detailed histological classification after panel review was available in 96% of the cases to allow selection of all cases with features potentially compatible with the WHO-definition of LRCHL for this study. Cases with dominance of lymphocytic infiltrate and relative paucity of eosinophils and fibrosis could be selected for re-classification. Twenty-one (0.8%) LRCHL cases were identified of which three were originally classified as NLPHL, seven as nodular sclerosis HL (NSHL) and 11 as mixed cellularity (MCHL), indicating that LRCHL is a rare disease.

Conclusions: Clinical evaluation of the unselected series of patients (n = 2743) showed that LRCHL and NLPHL cases more often presented with favorable features. Clinical outcome adjusted on ab initio patient prognosis did not differ between the three histological entities. These results strongly suggest that LRCHL corresponds to an early stage in the spectrum of cHL rather than a biologically different disease entity.

Key words: lymphocyte-rich classical Hodgkin lymphoma, lymphoma classification, clinical trial, prognosis


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 The OncologistHome page
A. I. Lee and A. S. LaCasce
Nodular Lymphocyte Predominant Hodgkin Lymphoma
Oncologist, July 1, 2009; 14(7): 739 - 751.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.